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To the EditorTo the Editor
Some Considerations for the Interpretation of Health-Related 
Quality of Life Data
 
To the Editor—Marquis et al. [1] recently proposed
a stepwise strategy for improving the understanding
and interpretation of health-related quality of life
(HRQL) measures. The strategy consists of two
mandatory steps: 1) understanding the content of
the scale and its psychometric properties (e.g., reli-
ability and construct validity), and 2) evaluating the
magnitude of the change, or of the treatment differ-
ence, and its statistical signiﬁcance through calcula-
tion of the effect size or standardized response mean
to demonstrate responsiveness. The authors further
suggest a supplemental step of selecting at least one
of three approaches to understand the clinical sig-
niﬁcance of changes in HRQL scores: 1) determining
the minimally important difference (MID), standard
error of measurement (SEM) or score calibration
using a global rating of change or a clinical anchor;
2) comparing baseline or follow-up scores with
norms or available known group references; or 3)
collecting data to understand the practical value of
scores, based on the relationship to outcomes such
as morbidity and death, patient behavior (compli-
ance and resource utilization) and consequences on
work (loss of productivity or working days). The
above methods are intended to help clinicians and
researchers understand the clinical relevance of a
change in score for a given HRQL measure.
While this approach is clearly presented in rele-
vant steps that appear to depict the state of the ﬁeld
and the general concepts follow those proposed by
Lydick and Epstein [2], caution should be taken in
proposing these as standards without other impor-
tant considerations.
For example, the observed effect size obviously
depends on the level of change found in a particular
study, and hence, the inherent effects of speciﬁc
interventions according to the characteristics of the
population being studied (for example, disease
severity or age). In addition, the interpretation of
effect sizes may vary widely according to condition;
small effect sizes may be meaningful to patients
with a certain disease, whereas in other conditions,
only moderate to large effect sizes may be important
to patients.
When using a global rating of change or a clinical
anchor, it should measure a related construct and
correlate to some degree with the questionnaire of
interest. The strength of the relationship of the
HRQL scores with the global rating of change or
clinical anchor should be characterized before cali-
brating the HRQL against such measures, and in
subsequent interpretation. Intuitively, one might
have greater conﬁdence in the calibration where a
stronger relationship is demonstrated between the
anchor and the questionnaire of interest compared
to a weaker relationship. This criterion is similar to
that used by Guyatt et al. [3] in which HRQL was
anchored to global transition ratings for change in
disease state.
The method of calibrating measures has also
been proposed to help understand the change in
HRQL scale scores in terms of life event changes
(for example, loss of a job or divorce), which are
presumably more understandable than changes
anchored to other measures. The example cited in
Marquis et al. calibrated changes in HRQL scores
to a Life Event scale [4]. Based on the calibration
method, “a change of 0.15 units was associated
with a 55-point change on the Life Events Index,
corresponding to the impact on quality of life that
single events, such as a major personal injury or ill-
ness (53 points), the death of a close family member
(63 points), or a dismissal from work (47 points),
might have on a person.” Nevertheless, there were
no differences on the Life Events scale reported dur-
ing the conduct of the study, nor were differences
found on efﬁcacy or safety parameters measured.
While cross-sectional correlations were discussed
(highest at week 8; range 0.36–0.57), there were no
longitudinal correlations provided to examine the
strength of the relationship for change in the HRQL
and the Life Events scale used for the calibration
(correlating changes in both scales over the same
period of time). Therefore, it is difﬁcult to know
how strongly the changes in the HRQL and Life
Events scales were correlated. Apart from using
such a Life Events scale, linking to outcomes such as
mortality or morbidity would necessitate large,
long-term trials which are not typically conducted
in traditional clinical trial programs.
As for MID, in cases where the correlations
between the anchor and the questionnaire of inter-
est may be low, there may be a great deal of varia-
bility in the distribution of the categories of the
anchor. This results in a misleading estimation of
MID. An additional step may be needed to ensure
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that the anchor is sufﬁciently related to the ques-
tionnaire to warrant such an approach. As others
have expressed, the estimated magnitude of any
MID will inherently depend on the distribution and
measurement properties of the external anchor [3].
The authors appropriately note the paradox of
using a single, nonvalidated item to calibrate a val-
idated multi-item questionnaire; the pitfalls of such
an approach are well-known [1].
Intuitively, the difference in the MID may vary
across a wide range of severity and tends to be
greater for populations with more severe disease
states. As Hays and Woolley suggest, the meaning of
change may depend on where you start [5]. Thus,
the MID may vary by the population being studied
[6]. Likewise, the MID would be dependent on the
distribution of the questionnaire domain scores as
well. Finally, the degree of change may depend on
the direction of change, and may not be of consist-
ent magnitude for those who deteriorate and those
who improve. In addition, insufﬁcient consideration
has been given to approaches aimed at documenting
the lack of disease progression in cases where the
goal of treatment is to maintain function while the
untreated group is expected to deteriorate.
For the supplemental step in determining clinical
signiﬁcance, collecting data in relevant clinical
severity groups and in nonsymptomatic groups may
be useful, but the well-known limitations of using
cross-sectional data as a basis for interpreting lon-
gitudinal change still apply. Likewise, one must be
cautious about the representativeness of the groups
selected on which the interpretation is being based,
and as the authors note, it may be difﬁcult to gen-
erate reference data for the general population.
Finally, the understanding of the practical value of
scores is certainly a laudable goal, but determining
the practical value in the manner in which the
authors propose may not be feasible for a new dis-
ease-speciﬁc measure being included in a clinical
trial program, particularly in new therapeutic
areas.—Josephine M. Norquist, Cindy J. Girman,
and Nancy C. Santanello, Department of Epidemi-
ology, Merck Research Laboratories, West Point,
PA, USA.
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